Loading your page…
Marketing-authorisation holder · United States
2 medicines in 1 country, as authorisation holder.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine in the registers under its name, current ones first.
2 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| APIXABAN1.5mg | 2.0mg | 2.5mg | 5mg · Tablet | Apixaban | United States | tentative | 2025 |
| SITAGLIPTIN100mg | 50mg · Tablet | Sitagliptin | United States | tentative | 2026 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 2 | 0 | 2 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.
